The gastrointestinal diseases drugs market covers medicines used for the treatment of ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome. The key gastrointestinal diseases drug categories include anti-peptic agents (antacids, antagonists, proton pump inhibitors, sucralfate, and misoprostol), antiemetics, adsorbents, anticholinergics, opiates, intestinal flora modifiers, emollient/surfactants, hyperosmotic, saline, and simulant/irritant.
The top five companies covered are Takeda Pharmaceuticals, Allergan Plc., Novo Nordisk A/S, AstraZeneca Plc and Johnson & Johnson. Takeda Pharmaceuticals was the largest company in the gastrointestinal diseases drugs market in 2017.
The countries covered are USA, China, Germany, Brazil, Japan, UK, Spain, Russia, France, Australia, Italy, India and rest of the world.
The global gastrointestinal drugs market was valued at above $54 billion in 2017. North America was the largest region in the gastrointestinal drugs market in 2017, accounting for above 30% market share. The USA was the largest country in the market in 2017, accounting for above 15% market share.
Drug manufacturing companies are offering tranexamic acid for the treatment of acute gastrointestinal bleeding. Tranexamic acid is a medication used to treat or prevent excessive blood loss from major trauma or surgery and is now finding applications for gastrointestinal diseases. Tranexamic acid reduces clot breakdown, thus reducing the duration and amount of bleeding. This reduces mortality rate (from 10% to 7.5%) and the probability of blood transfusion by about 30%. Major companies manufacturing tranexamic acid include Abbott Laboratories, Pfizer, GlaxoSmithKline and Bayer AG.